Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. Amit Hasija, CFO, and Lorenz Muller, Chief Commercial Officer, will speak.
A live webcast is scheduled for March 3, 2026 at 9:10 AM EST, with a replay available for approximately 90 days on the company website. Meetings can be requested through TD Cowen representatives.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
MIST was down 0.57% with below-average volume, while only one peer in momentum (KYTX) showed an up move, suggesting the conference announcement is being treated as stock-specific rather than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Executive appointment | Neutral | +1.1% | Appointment of General Counsel and Chief Compliance Officer during CARDAMYST launch. |
| Feb 03 | Equity inducement grants | Neutral | +0.5% | Inducement stock options granted to new employees under 2021 Inducement Plan. |
| Jan 26 | Product launch | Positive | -2.0% | U.S. commercial availability of CARDAMYST nasal spray for adult PSVT treatment. |
| Jan 06 | EMA filing accepted | Positive | +1.5% | EMA acceptance of MAA for etripamil (TACHYMIST) in PSVT with large EU population. |
| Dec 17 | Device partnership | Positive | -3.3% | Aptar announcement that its Bidose system delivers FDA-approved CARDAMYST nasal spray. |
Recent news shows mixed alignment: positive regulatory and product milestones sometimes coincided with negative 24h price reactions, while other positive updates saw modest gains.
Over the past few months, Milestone issued several important updates. In December 2025, FDA approval for CARDAMYST nasal spray was followed in January 2026 by U.S. commercial availability and an EMA MAA acceptance for etripamil (TACHYMIST), targeting about 2 million PSVT patients in Europe. Governance and compensation updates included insider equity awards and a new General Counsel appointment effective Feb 10, 2026. Against this backdrop, the TD Cowen conference appearance fits into ongoing commercialization and investor-relations efforts.
Market Pulse Summary
This announcement highlights Milestone’s participation at a major healthcare conference, offering updated visibility into the commercial rollout of CARDAMYST and broader corporate strategy. Recent milestones include FDA approval in December 2025, U.S. commercial availability in January 2026, and EMA acceptance of an MAA targeting about 2 million PSVT patients in Europe. Investors may focus on how management frames launch progress, market access, and upcoming regulatory timelines during the March 2–4, 2026 TD Cowen event.
AI-generated analysis. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.
A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
FAQ
When will Milestone (MIST) present at the TD Cowen 46th Annual Health Care Conference?
How can investors watch the Milestone (MIST) webcast for the TD Cowen conference?
Who from Milestone (MIST) will present at the TD Cowen 46th Annual Health Care Conference?
How long will the Milestone (MIST) conference presentation replay remain available online?
How can investors request a meeting with Milestone (MIST) at the TD Cowen conference?
What topics will Milestone (MIST) cover in its TD Cowen 2026 presentation?
